Reduced Competition Adds $35 to Regeneron (REGN) DCF, Deutsche Bank Raises PT to $310
Deutsche Bank today maintained a Buy rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $310.00 (from ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)